Marker Therapeutics, Inc. (MRKR) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to Marker Therapeutics conference call. At this time, all participants are in listen-only mode. Later, we'll conduct a question-and-answer session, and instructions will be given at that time. As a reminder, this conference call is being recorded. It's now my pleasure to turn the call over to Mr. Tony Kim, Chief Financial Officer at Marker. Mr. Kim, please go ahead. Thanks, Operator. Welcome, everyone, and thank you for joining us this afternoon for our clinical program and technical operations update call. With me today are Peter Huang, our President and Chief Executive Officer, Dr. Juan Vera, our Chief Scientific and Chief Operating Officer, and Dr. Maithili Connero, our Chief Medical Officer. This afternoon, we issued a news release that you can find on our website at markettherapeutics.com, which includes a summary of initial results from the safety lead-in portion of our Phase II AML trial, as well as updates on our new manufacturing process and an overview of our near-term clinical plans. Before we begin, as a reminder, we will be making forward-looking statements regarding our financial outlook in addition to regulatory, product development, and commercialization plans and research activities. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent 10-K on file with the SEC. I would now like to turn the call over to Peter. Good afternoon, everyone, and thank you for joining us today. Marker's off to a strong start in 2022, and we've made considerable progress in advancing our Phase 2 AML trial. In just a moment, I'll be making a few remarks about our company's progress and provi...